Biological research: Rethink biosafety.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Exploring the Impact of Tensions in Stakeholder Norms on Designing for Value Change: The Case of Biosafety in Industrial Biotechnology.Science and engineering ethics · 2023
   Article
2. Advances in nanotechnology application in biosafety materials: A crucial response to COVID-19 pandemic.Biosafety and health · 2022
   Review
3. Development and Validation of Biosafety Climate Scale for Biological and Biomedical Science Laboratories in the United States.Applied biosafety : journal of the American Biological Safety Association · 2021
   Article
4. Harmonization of Biosafety and Biosecurity Standards for High-Containment Facilities in Low- and Middle-Income Countries: An Approach From the Perspective of Occupational Safety and Health.Frontiers in public health · 2019
   Review
5. Safe-by-Design: from Safety to Responsibility.Nanoethics · 2017
   Article
6. Survey of laboratory-acquired infections around the world in biosafety level 3 and 4 laboratories.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016
   Article
7. Safety culture: Nuclear industry no model for biosafety.Nature · 2015
   Article
8. Motivating Proactive Biorisk Management.Health security
   Review

Corrections and comments

• Commented on by
  Safety culture: Nuclear industry no model for biosafety.2015

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as